 Anosheh Afghahi
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 14 | 2025 | 2142 | 1.750 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2018 | 197 | 1.370 |
Why?
| | BRCA2 Protein | 4 | 2024 | 53 | 0.970 |
Why?
| | BRCA1 Protein | 4 | 2024 | 65 | 0.960 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.700 |
Why?
| | Cancer Survivors | 2 | 2022 | 263 | 0.640 |
Why?
| | Sexual Health | 1 | 2020 | 54 | 0.640 |
Why?
| | Lymphocyte Count | 1 | 2018 | 148 | 0.580 |
Why?
| | Genetic Testing | 2 | 2017 | 428 | 0.550 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1181 | 0.540 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 54 | 0.480 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 150 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 964 | 0.450 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 170 | 0.450 |
Why?
| | Genomics | 2 | 2016 | 716 | 0.430 |
Why?
| | Germ-Line Mutation | 3 | 2019 | 140 | 0.410 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 390 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2282 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1706 | 0.310 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2061 | 0.280 |
Why?
| | Genes, BRCA1 | 2 | 2017 | 32 | 0.270 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 90 | 0.260 |
Why?
| | SEER Program | 2 | 2018 | 206 | 0.260 |
Why?
| | Neoplasm Staging | 3 | 2025 | 1295 | 0.250 |
Why?
| | Middle Aged | 13 | 2025 | 31150 | 0.210 |
Why?
| | Multiple Myeloma | 1 | 2025 | 125 | 0.210 |
Why?
| | Oligopeptides | 1 | 2025 | 257 | 0.210 |
Why?
| | Quality of Life | 3 | 2025 | 2704 | 0.200 |
Why?
| | Amyloidosis | 2 | 2013 | 42 | 0.200 |
Why?
| | Female | 19 | 2025 | 68770 | 0.200 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 28 | 0.200 |
Why?
| | Prophylactic Mastectomy | 1 | 2021 | 8 | 0.180 |
Why?
| | Aged | 8 | 2025 | 22099 | 0.180 |
Why?
| | Humans | 22 | 2025 | 129622 | 0.180 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 372 | 0.180 |
Why?
| | Receptor, ErbB-2 | 3 | 2023 | 326 | 0.180 |
Why?
| | Chemoprevention | 1 | 2021 | 91 | 0.180 |
Why?
| | Mutation | 4 | 2024 | 3717 | 0.180 |
Why?
| | Neoplasms | 1 | 2015 | 2470 | 0.170 |
Why?
| | Resistance Training | 1 | 2022 | 151 | 0.170 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 490 | 0.160 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 383 | 0.150 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 44 | 0.150 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2018 | 40 | 0.150 |
Why?
| | Carcinoma, Lobular | 1 | 2018 | 48 | 0.150 |
Why?
| | Adult | 9 | 2025 | 35572 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2018 | 71 | 0.140 |
Why?
| | Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2017 | 3 | 0.140 |
Why?
| | Genes, BRCA2 | 1 | 2017 | 24 | 0.140 |
Why?
| | Penetrance | 1 | 2017 | 27 | 0.140 |
Why?
| | Platinum | 1 | 2017 | 44 | 0.130 |
Why?
| | California | 1 | 2018 | 401 | 0.130 |
Why?
| | Carboplatin | 1 | 2017 | 140 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1266 | 0.130 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 243 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 211 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 307 | 0.120 |
Why?
| | Imatinib Mesylate | 1 | 2015 | 76 | 0.120 |
Why?
| | Trastuzumab | 1 | 2015 | 101 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 864 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1201 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2015 | 285 | 0.110 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 118 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 302 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 315 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1565 | 0.110 |
Why?
| | Prognosis | 2 | 2023 | 3794 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 485 | 0.110 |
Why?
| | Melphalan | 1 | 2013 | 29 | 0.110 |
Why?
| | Immunoglobulin Light Chains | 1 | 2013 | 40 | 0.100 |
Why?
| | Thalidomide | 1 | 2013 | 32 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 589 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 383 | 0.100 |
Why?
| | Laryngeal Diseases | 1 | 2012 | 28 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 759 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7084 | 0.090 |
Why?
| | Dexamethasone | 1 | 2013 | 346 | 0.090 |
Why?
| | Immunotherapy | 1 | 2015 | 592 | 0.090 |
Why?
| | Macrophages | 1 | 2018 | 1480 | 0.090 |
Why?
| | Prevalence | 1 | 2017 | 2564 | 0.090 |
Why?
| | Registries | 1 | 2018 | 1895 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 350 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 893 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2016 | 975 | 0.080 |
Why?
| | Melanoma | 1 | 2015 | 730 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1501 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3240 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 825 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 5401 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 3973 | 0.070 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 22 | 0.060 |
Why?
| | Workflow | 1 | 2025 | 155 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 33 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 14 | 0.050 |
Why?
| | Risk Factors | 1 | 2017 | 9763 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 33 | 0.050 |
Why?
| | Homologous Recombination | 1 | 2022 | 23 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 51 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 61 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2344 | 0.050 |
Why?
| | Breast | 1 | 2023 | 153 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2023 | 381 | 0.050 |
Why?
| | Body Image | 1 | 2022 | 84 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2022 | 521 | 0.040 |
Why?
| | Mammography | 1 | 2021 | 146 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 461 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2019 | 48 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 334 | 0.040 |
Why?
| | Young Adult | 1 | 2015 | 12426 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2018 | 51 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2018 | 57 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2021 | 14519 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 10226 | 0.040 |
Why?
| | Aminopyridines | 1 | 2018 | 97 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2022 | 483 | 0.040 |
Why?
| | Purines | 1 | 2018 | 172 | 0.040 |
Why?
| | Mastectomy | 1 | 2018 | 131 | 0.030 |
Why?
| | Benzimidazoles | 1 | 2018 | 162 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2018 | 343 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 683 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1274 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 342 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 610 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 426 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1245 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 478 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 945 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 891 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 857 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3381 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2012 | 97 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3215 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1040 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3408 | 0.020 |
Why?
| | Metastrongyloidea | 1 | 1969 | 1 | 0.020 |
Why?
| | Mollusca | 1 | 1969 | 6 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1877 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1097 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1587 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1434 | 0.020 |
Why?
| | Male | 3 | 2025 | 63674 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 5420 | 0.010 |
Why?
| | Mice | 1 | 2018 | 16937 | 0.010 |
Why?
| | Animals | 2 | 2018 | 35360 | 0.010 |
Why?
| | Parasitic Diseases, Animal | 1 | 1969 | 5 | 0.000 |
Why?
| | Snails | 1 | 1969 | 34 | 0.000 |
Why?
| | Dog Diseases | 1 | 1969 | 52 | 0.000 |
Why?
| | Ecology | 1 | 1969 | 108 | 0.000 |
Why?
| | Dogs | 1 | 1969 | 381 | 0.000 |
Why?
| | Aging | 1 | 1969 | 1776 | 0.000 |
Why?
|
|
Afghahi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|